{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-074975","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.995501+00:00","generated_at":"2026-05-17T14:56:49.128674+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TherapeuticsMD Q2 net income $545K vs loss last year; license revenue up to $1.0M","bullets":["Net income from continuing operations $545K ($0.05/share) vs net loss of -$1.05M (-$0.09) in Q2 2024.","License revenue $1.0M, up $0.7M from $234K, driven by changes in Mayne License Agreement product sales.","Total operating expenses fell 45.5% to $1.647M, primarily due to no impairment in current quarter.","Cash and equivalents $6.1M as of June 30, 2025; company continues strategic alternatives review.","No timetable set for strategic transaction outcome; no assurance of any deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-074975","json":"https://secwatch.observer/filing/0001213900-25-074975.json","markdown":"https://secwatch.observer/filing/0001213900-25-074975.md","text":"https://secwatch.observer/filing/0001213900-25-074975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390025074975/0001213900-25-074975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390025074975/ea0252348-8k_therap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:56:49.128674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}